Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Information is needed to manage pregnancies with inadvertent exposure to baricitinib. A total of 117 pregnancies with exposure to baricitinib were identified among patients treated with baricitinib for rheumatoid arthritis, atopic dermatitis, or alopecia areata during clinical trials or in the postmarketing setting, and retrieved from the Eli Lilly global safety database. The clinical outcomes of the pregnancies with reported exposure to baricitinib appear to be comparable to those previously reported with other targeted therapies for immune-mediated diseases or in the general population.

Automated summary

A total of 117 pregnancies with exposure to baricitinib were analyzed, and the clinical outcomes were found to be comparable to other targeted therapies for immune-mediated diseases or general population.